- Home
- HOUR vs EQ Comparison
HOUR vs EQ Comparison
Compare HOUR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUR
- EQ
- Stock Information
- Founded
- HOUR 2015
- EQ 2017
- Country
- HOUR United States
- EQ United States
- Employees
- HOUR N/A
- EQ N/A
- Industry
- HOUR Catalog/Specialty Distribution
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- HOUR Consumer Discretionary
- EQ Health Care
- Exchange
- HOUR Nasdaq
- EQ Nasdaq
- Market Cap
- HOUR 63.3M
- EQ 67.9M
- IPO Year
- HOUR 2022
- EQ 2018
- Fundamental
- Price
- HOUR $1.52
- EQ $1.82
- Analyst Decision
- HOUR
- EQ Buy
- Analyst Count
- HOUR 0
- EQ 3
- Target Price
- HOUR N/A
- EQ $3.00
- AVG Volume (30 Days)
- HOUR 22.1K
- EQ 23.5M
- Earning Date
- HOUR 08-12-2025
- EQ 08-14-2025
- Dividend Yield
- HOUR N/A
- EQ N/A
- EPS Growth
- HOUR N/A
- EQ N/A
- EPS
- HOUR 0.02
- EQ N/A
- Revenue
- HOUR $138,441,228.00
- EQ $16,553,000.00
- Revenue This Year
- HOUR N/A
- EQ N/A
- Revenue Next Year
- HOUR N/A
- EQ N/A
- P/E Ratio
- HOUR $67.34
- EQ N/A
- Revenue Growth
- HOUR N/A
- EQ N/A
- 52 Week Low
- HOUR $1.10
- EQ $0.27
- 52 Week High
- HOUR $6.90
- EQ $2.26
- Technical
- Relative Strength Index (RSI)
- HOUR 37.65
- EQ 74.99
- Support Level
- HOUR $1.46
- EQ $1.70
- Resistance Level
- HOUR $1.60
- EQ $2.23
- Average True Range (ATR)
- HOUR 0.09
- EQ 0.33
- MACD
- HOUR -0.04
- EQ 0.08
- Stochastic Oscillator
- HOUR 12.88
- EQ 70.27
About HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.